Related references
Note: Only part of the references are listed.A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab
Jeffrey D. Kearns et al.
SCIENCE TRANSLATIONAL MEDICINE (2023)
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
Axel Ducret et al.
MABS (2022)
Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome
Laura Santambrogio
FRONTIERS IN IMMUNOLOGY (2022)
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
Yanchen Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Validation of a Dendritic Cell and CD4+T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics
Michel Siegel et al.
PHARMACEUTICS (2022)
Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Pilar Martinez Sanchez et al.
BLOOD (2021)
A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)
Giuseppe Rossi et al.
BLOOD (2021)
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
Horst-Dieter Hummel et al.
IMMUNOTHERAPY (2021)
Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses
Aurelien Azam et al.
FRONTIERS IN IMMUNOLOGY (2021)
Managing the impact of immunogenicity in an era of immunotherapy: from bench to bedside
Katharine Bray-French et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies
Mimmi L. E. Lundahl et al.
RSC CHEMICAL BIOLOGY (2021)
T cell epitope mapping of secukinumab and ixekizumab in healthy donors
Sebastian Spindeldreher et al.
MABS (2020)
Applying MAPPs Assays to Assess Drug Immunogenicity
Anette C. Karle
FRONTIERS IN IMMUNOLOGY (2020)
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020
Vibha Jawa et al.
FRONTIERS IN IMMUNOLOGY (2020)
Impact of Precipitation of Antibody Therapeutics After Subcutaneous Injection on Pharmacokinetics and Immunogenicity
Francis Kinderman et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Jasmine Davda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1
Lora Hamuro et al.
AAPS JOURNAL (2019)
Immunogenicity of biologic therapies: causes and consequences
Wolf-Henning Boehncke et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins
Zuben E. Sauna et al.
TRENDS IN BIOTECHNOLOGY (2018)
Immunosilencing peptides by stereochemical inversion and sequence reversal: retro-D-peptides
Pol Arranz-Gibert et al.
SCIENTIFIC REPORTS (2018)
MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity
Nobuo Sekiguchi et al.
MABS (2018)
Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins
Lora Hamuro et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors
Moustafa Hamze et al.
FRONTIERS IN IMMUNOLOGY (2017)
Subcutaneous drug delivery: An evolving enterprise
Graham B. Jones et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development
Laura I. Salazar-Fontana et al.
AAPS JOURNAL (2017)
Immunogenicity of Therapeutic Protein Aggregates
Ehab M. Moussa et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
Emilie M. J. van Brummelen et al.
ONCOLOGIST (2016)
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes
Murli Krishna et al.
FRONTIERS IN IMMUNOLOGY (2016)
From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity
Natalie L. Trevaskis et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies
Sue Townsend et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Analysis of Glucocorticoid Receptors and Their Apoptotic Response to Dexamethasone in Male Murine B Cells During Development
Amanda L. Gruver-Yates et al.
ENDOCRINOLOGY (2014)
The origins and functions of dendritic cells and macrophages in the skin
Bernard Malissen et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics
Li Xue et al.
AAPS JOURNAL (2013)
Subcutaneous abatacept for the treatment of rheumatoid arthritis
Michael Schiff
RHEUMATOLOGY (2013)
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Narendra Chirmule et al.
AAPS JOURNAL (2012)
Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses
Marisa K. Joubert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
The Role of Naive T Cell Precursor Frequency and Recruitment in Dictating Immune Response Magnitude
Marc K. Jenkins et al.
JOURNAL OF IMMUNOLOGY (2012)
Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors
Stephanie Delluc et al.
FASEB JOURNAL (2011)
Immunogenicity of different brands of human insulin and rapid-acting insulin analogs in insulin-naive children with type 1 diabetes
B. Mianowska et al.
PEDIATRIC DIABETES (2011)
The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions
Fiona A. Harding et al.
MABS (2010)
Effect of Route of Administration of Human Recombinant Factor VIII on Its Immunogenicity in Hemophilia A Mice
Aaron Peng et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antibody structure, instability, and formulation
Wei Wang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells
W Hoetzenecker et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity
AA Itano et al.
IMMUNITY (2003)
Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes
C Ruedl et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
